Aromatase inhibitors in gynecologic cancers
- 30 September 2007
- journal article
- review article
- Published by Elsevier BV in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 106 (1-5), 76-80
- https://doi.org/10.1016/j.jsbmb.2007.05.026
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancerJournal of Clinical Oncology, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancerGynecologic Oncology, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian CancerOncology, 2004
- Phase II trial of anastrozole in women with asymptomatic müllerian cancerGynecologic Oncology, 2003
- Tamoxifen Therapy for Ovarian Cancer in the Adjuvant and Advanced Settings: Systematic Review of the Literature and Implications for Future ResearchGynecologic Oncology, 2002
- Intratumoral Aromatase in Human Breast, Endometrial, and Ovarian MalignanciesEndocrine Reviews, 1998
- Whither TamoxifenGynecologic Oncology, 1996
- Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second-line therapy in 105 patientsCancer, 1991